Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.
Dig Dis Sci 56(1):131-8 (2011) PMID 20503071
Platinum and 5-fluorouracil (5-FU)-based regimens have been used the most frequently in palliative chemotherapy for gastric cancer. The present study evaluated the prognostic significance of Bax, excision repair cross-complementation group 1 (ERCC1), and thymidylate synthase (TS) in advanced gastric cancer patients treated with 5-FU, leucovorin, and oxaliplatin (FOLFOX) palliative chemotherapy.
DOI: 10.1007/s10620-010-1280-8
Version: za2963e q8za7 q8zb5 q8zcd q8zdd q8zec q8zf3 q8zgb